Project Oncology®

In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

Here to give highlights from the “Finetuning Risk Assessment and Risk Reduction” session at the 2021 San Antonio Breast Cancer Symposium (SABCS) is Dr. Banu Arun, Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Genetics for the MD Anderson Cancer Networks.

As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.

Did you know that HER2 mutations can be found in about 4 percent of patients with non-small cell lung cancer (NSCLC)? Although it’s not a very common genetic event, it’s still important to know how these mutations drive disease progression and how you can treat these NSCLC patients. That’s why Dr. Sandra Misale joins Dr. Hector Chapa to explore the clinical features and characteristics of HER2 mutations along with the available therapeutic options.

Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.

While lymphoma can sometimes be difficult to treat, emerging therapies and clinical developments are on the horizon. But could they help improve patient outcomes? Dr. Jacob Sands is joined by Dr. Joseph Tuscano, Physician and Professor of Hematology and Oncology at UC Davis Comprehensive Cancer Center to talk about updates in Lymphoma treatment.

How can we better diagnose and treat patients with HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Nicolas Girard and Dr. Jack West to explore diagnostic and therapeutic challenges and share collaborative patient management strategies for these patients.

From causes to counseling strategies, Dr. Lindsey Roeker joins Dr. Jennifer Caudle to dive into chronic lymphocytic leukemia fatigue and how we can help our patients who are experiencing this kind of fatigue.

Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.

This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.

Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine and Dr. Ehab Atallah, a Professor of Medicine and Section Head of Hematological Malignancies in the Medical College of Wisconsin’s Division of Hematology and Oncology join Dr. Charles Turck to explore collaborative approaches and share best practices in the management of chronic lymphocytic leukemia.